Profiel
Anat Kerem-Angel served as a Director at Thrombotech Ltd.
She also worked as an Associate at Youdim Pharmaceuticals Ltd.
from 2004 to 2010.
Dr. Kerem-Angel holds a doctorate degree from Tel-Aviv University.
Eerdere bekende functies van Anat Kerem-Angel
| Bedrijven | Functie | Einde |
|---|---|---|
Youdim Pharmaceuticals Ltd.
 Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Private Equity Investor | 31-12-2010 |
Thrombotech Ltd.
 Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Directeur/Bestuurslid | - |
Opleiding van Anat Kerem-Angel
| Tel-Aviv University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Youdim Pharmaceuticals Ltd.
Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Finance |
Thrombotech Ltd.
Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Health Technology |
